RxDoctor Payments Data

Charles Hendrix, MD

Internal Medicine · Vincennes, INNPI 1437101128

Payments from drug & device makers

$7,123in general payments, 2019–2025

Across 518 payments — averaging $13.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$770
  • AstraZeneca$691
  • Amgen$595
  • Pfizer$548
  • Johnson & Johnson$482
  • GSK$456
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,07799%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,123 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$363,864
Medicare patients
1,078
Services billed
11,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban995$488,489
OzempicSemaglutide180$185,761
JardianceEmpagliflozin244$161,715
XareltoRivaroxaban206$99,222
JanuviaSitagliptin Phosphate101$94,867
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$86,666
FarxigaDapagliflozin Propanediol179$86,285
LinzessLinaclotide106$61,606
EntrestoSacubitril/Valsartan97$51,588
MyrbetriqMirabegron148$45,378
Tresiba Flextouch U-200Insulin Degludec56$40,911
RexultiBrexpiprazole34$40,410
XifaxanRifaximin14$39,657
GemtesaVibegron131$39,466
NuedextaDextromethorphan Hbr/Quinidine50$37,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$548$503,6331,008 claims
Novo NordiskOzempic, Tresiba, Fiasp$770$218,121275 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$99$200,042327 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy$456$137,607235 claims
Johnson & JohnsonXarelto, Invokana$482$112,699230 claims
MerckJanuvia, Janumet$82$112,318113 claims
AstraZenecaFarxiga$691$86,285179 claims
Lilly USA, LLCMounjaro, Trulicity$415$63,17662 claims
AbbVieLinzess$452$61,606106 claims
NovartisEntresto$447$51,58897 claims
Astellas Pharma US IncMyrbetriq$227$45,378148 claims
Otsuka America Pharmaceutical, Inc.Rexulti$161$40,41034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Vincennes

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →